DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Lung Sclerosing Hemangioma — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLung Sclerosing Hemangioma maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lung sclerosing hemangioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
What the evidence adds up to
A 57-year-old woman had a solitary nodule in the left lung removed by wedge resection; pathological examination confirmed pulmonary sclerosing hemangioma. She received no postoperative adjuvant therapy. Ten years later a nodule reappeared at the same site and another wedge resection was performed, again confirming sclerosing hemangioma. The authors note that recurrence of this tumour is very rare. In another case, a patient presented with respiratory arrest secondary to bilateral mechanical airway obstruction caused by endobronchial sclerosing hemangioma of the left main bronchus; such a presentation had not been described before and proved a challenging diagnosis. Endobronchial growth of sclerosing hemangioma is extremely rare, with only three reported cases in the literature at the time of that report.
Three cases managed differently are described in a 2003 report. The authors state that thoracic surgeons should raise awareness of this benign slow-growing tumour in the differential diagnosis of solitary pulmonary nodule. Radiographic evidence of expansion of a lesion is not conclusive for malignancy and should not affect its biological behaviour. Intraoperative frozen-section histology may prevent unnecessary resection of lung tissue. Extracapsular enucleation is described as the treatment of choice for sclerosing hemangiomas. An earlier 1990 report describes three cases in women aged 54, 52, and 51 years, noting that sclerosing hemangioma of the lung is an uncommon benign neoplasm of uncertain histogenesis and that its radiologic appearance is relatively distinct and well defined.
No drug treatment is mentioned in any of these abstracts. The evidence consists entirely of case reports and small case series, with no controlled trials, no prospective data, and no comparative effectiveness data. What is still missing is any systematic investigation of medical therapy, any trial design that could test a drug, any patient stratification beyond surgical pathology, and any funding for such research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Thoracic and Cardiovascular Surgeon · 2008 · 50 citations
Recurrence of Pulmonary Sclerosing Hemangioma
AbstractA 57-year-old woman with a solitary nodule in the left lung underwent a wedge resection, which resulted in total removal of the tumor. Pathological examination confirmed it to be a pulmonary sclerosing hemangioma. The patient did not receive any postoperative adjuvant therapies. Ten years later, a nodule reappeared at the same site and another wedge resection was performed. Pathological examination once again confirmed the diagnosis of sclerosing hemangioma. However, the recurrence of pulmonary sclerosing hemangioma is very rare; thus, we report here on one clinical case in detail.
Respiratory Arrest Caused by Endobronchial Sclerosing Hemangioma of the Left Main Bronchus
AbstractSclerosing hemangioma is a rare pulmonary tumor that usually grows as a peripheral intraparenchymal lesion in the lungs. Although some case series have described this rare tumor, endobronchial growth of sclerosing hemangioma is extremely rare, with only 3 reported cases in the literature to date. We describe a patient who presented with respiratory arrest secondary to bilateral mechanical airway obstruction caused by this tumor. Such a presentation has never been described in the literature before and, as such, proved to be a challenging diagnosis.
Asian Cardiovascular and Thoracic Annals · 2003 · 2 citations · open access
Pulmonary Sclerosing Hemangiomas: New Approach in Patients with Low Cancer Risk
AbstractThree cases of sclerosing hemangioma managed differently are described. Thoracic surgeons should raise their awareness of this benign slow-growing tumor in the differential diagnosis of solitary pulmonary nodule. Radiographic evidence of expansion of such a lesion is not conclusive for malignancy, and should not affect its biological behavior. Intraoperative frozen-section histology may prevent unnecessary resection of lung tissue. Extracapsular enucleation is the treatment of choice for sclerosing hemangiomas.
Yeungnam University Journal of Medicine · 1990 · 0 citations · open access
Sclerosing hemangioma of lung: 3 case report
AbstractSclerosing hemangioma of the lung is uncommon benign neoplasm of uncertain histogenesis. Their radiologic appearance is relatively distinct and well defined. Recently we experienced 3 cases of sclerosing hemangioma of the lung in 54, 52, 51 years old women. The light microscopic findings are similar to the features reported by Liebow and Hubbell(1956).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
